Alkermes plc (NASDAQ: ALKS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Alkermes is the commercial-stage company in our coverage that faced some of the most pressure in 1Q20 from the COVID-19 pandemic, as sales of key products Aristada and Vivitrol (both of which need to be administered to patients by healthcare professionals) suffered and the company pulled its FY 2020 guidance. Things seem to be stabilizing now, with the company delivering 2Q20 results that beat expectations on the top and bottom line and reinstating FY 2020 guidance that brackets Consensus. The stock is up 50%+ from its May 1 lows, and today’s results should be generally well-received, but we maintain our Neutral rating while looking for more meaningful drivers of longer-term upside.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, visit the company’s website at www.Alkermes.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork